Recently, adjuvant treatment of resected stage IB–IIIA EGFR-mutated non-small cell lung cancer (NSCLC) with the 3rd generation EGFR-TKI osimertinib in the ADAURA clinical trial showed significantly better outcomes than that of the placebo [10]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.